PARSIPPANY, N.J., April 18, 2014 /PRNewswire/ -- Daiichi
Sankyo, Inc. announced today that Ken
Keller will join the company as President of its Commercial
operations in the United States
starting May 1, 2014. In his
role, Mr. Keller will be responsible for leading marketing, sales,
medical affairs and supply chain operations for Daiichi Sankyo in
the U.S.
"We are very pleased to welcome Ken
Keller into the Daiichi Sankyo family," said Joji Nakayama, President and CEO of Daiichi
Sankyo Co., Ltd., the parent company of the Daiichi Sankyo
Group. "Ken brings with him more than 25 years of
pharmaceutical experience, with career highlights including
building a $3 billion business unit
as well as leading commercialization for four of the world's top
selling biologic medicines. His broad experience and proven
success will be a tremendous asset to Daiichi Sankyo."
Most recently, Mr. Keller was Executive Vice President and Chief
Operating Officer at Spectrum Pharmaceuticals, where he was
responsible for global commercial, medical, research and
development, and manufacturing. Also responsible for business
development at Spectrum, he was integral to the successful
acquisition and integration of Talon Therapeutics into the
company.
Prior to Spectrum, Mr. Keller spent 21 years at Amgen rising
through the organization as a respected leader in sales and
marketing, general management and joint ventures. He brings
with him deep experience in several therapeutic areas aligned with
Daiichi Sankyo's focus, including oncology and primary care
medicines. His most recent appointments at Amgen were as Vice
President and General Manager for two of the company's highly
successful business units (bone health and inflammation), as well
as Managing Director at Amgen Limited in the United Kingdom and Ireland.
With the appointment of Mr. Keller as the head of commercial
operations at Daiichi Sankyo, Inc., Dr. Glenn Gormley will assume the role of Executive
Chairman and President, Daiichi Sankyo, Inc., and will retain his
roles as President, Daiichi Sankyo Pharma Development and as the
Global Head of R&D for Daiichi Sankyo Co., Ltd.
Greg Barrett, who served as interim
president for Commercial operations for the past seven months, will
remain Vice President of Marketing and Managed Markets at Daiichi
Sankyo, Inc.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of
innovative pharmaceutical products to address the diversified,
unmet medical needs of patients in both mature and emerging
markets. While maintaining its portfolio of marketed
pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments
for thrombotic disorders and focused on the discovery of novel
oncology and cardiovascular-metabolic therapies. Furthermore, the
Daiichi Sankyo Group has created a "Hybrid Business Model," which
will respond to market and customer diversity and optimize growth
opportunities across the value chain. For more information, please
visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the
Daiichi Sankyo Group. For more information on Daiichi Sankyo,
Inc., please visit www.dsi.com.
SOURCE Daiichi Sankyo, Inc.